Melanoma News

CancerConnect melanoma news, tips, and features provide breaking research stories, helpful tips, and inspiring features related to ovarian cancer. The unique daily cancer news service evaluates all aspects of melanoma research and reports on the developments that are most important to cancer patients and healthcare providers, while the tips and features offer insight into all aspects of melanoma treatment and survivorship.

Share

Melanoma News


Moffitt Researchers Discover Mechanism Leading to Drug Resistance, Metastasis in Melanoma Patients (January 9, 2015)

TAMPA, Fla. – Moffitt Cancer Center researchers have discovered a mechanism that leads to resistance to targeted therapy in melanoma patients and are investigating strategies to counteract it. Targeted... Continue Reading

Melanoma Research News: Year in Review (January 7, 2015)

After several years of exciting developments in melanoma therapy, progress continued throughout 2014. Doctors specializing in the treatment of melanoma reported continued progress about optimizing the... Continue Reading

FDA Approves Nivolumab for Advanced Melanoma (December 23, 2014)

CancerConnect News: The FDA granted accelerated approval to nivolumab (Opdivo) for patients with unresectable or metastatic melanoma who no longer respond to other drugs. Nivolumab, a PD-1 inhibitor, is... Continue Reading

Final Budget Bill Doubles DoD Funding Available for Melanoma Research (December 11, 2014)

The Melanoma Research Alliance (MRA) hailed the inclusion in the omnibus appropriations bill providing government funding for Fiscal Year 2015 of $50 million in funding for the Department of Defense’s... Continue Reading

Yervoy® May be Beneficial in Uveal Melanoma (December 8, 2014)

CancerConnect News:The first trial of the immunomodulator Yervoy® (ipilimumab) conducted in patients with uveal melanoma appears promising in according to the results of a small clinical trial presented... Continue Reading

PV-10 Injection Promising Treatment of Melanoma Lesions (November 25, 2014)

The results of an international clinical trial evaluating the use of intralesional rose bengal (PV-10), injected in 80 patients with refractory cutaneous or subcutaneous metastatic melanoma were recently... Continue Reading

Memorial Sloan Kettering Team Makes Key Discovery in Understanding Immunotherapy’s Successes—And Its Failures (November 24, 2014)

A collaborative team of leaders in the field of cancer immunology from Memorial Sloan Kettering Cancer Center has made a key discovery that advances the understanding of why some patients respond to ipilimumab,... Continue Reading

Nivolumab Superior to Chemotherapy in First Phase III Trial as Initial Treatment in Advanced Melanoma (November 20, 2014)

The immunotherapy drug nivolumab produces significantly better overall survival than chemotherapy as initial treatment in advanced melanoma, according to findings from its first Phase III study in previously... Continue Reading

Thin Melanomas Responsible for Many Melanoma Related Deaths (November 19, 2014)

According to a new study published in The Journal of Investigative Dermatology, more people are dying from melanomas thinner than a dime than from thicker skin lesions, which have long been thought to... Continue Reading

MRA Applauds Congress for Getting the Sunscreen Innovation Act over the Goal Line (November 17, 2014)

(OMNI-CancerConnect) — The Melanoma Research Alliance (MRA) applauds the House for acting on the Senate-passed Sunscreen Innovation Act, clearing the way for the President’s signature. Thanks to the... Continue Reading

More Melanoma News

Latest Melanoma News By Stage


Screening/Prevention

Melanoma Research News: Year in Review (January 7, 2015)

After several years of exciting developments in melanoma therapy, progress continued throughout 2014. Doctors specializing in the treatment of melanoma reported continued progress about optimizing the use of BRAF inhibitors and the long awaited PD-1 immunotherapy... Continue Reading

Thin Melanomas Responsible for Many Melanoma Related Deaths (November 19, 2014)

According to a new study published in The Journal of Investigative Dermatology, more people are dying from melanomas thinner than a dime than from thicker skin lesions, which have long been thought to be more dangerous. Researchers in Australia wanted... Continue Reading

MRA Applauds Congress for Getting the Sunscreen Innovation Act over the Goal Line (November 17, 2014)

(OMNI-CancerConnect) — The Melanoma Research Alliance (MRA) applauds the House for acting on the Senate-passed Sunscreen Innovation Act, clearing the way for the President’s signature. Thanks to the leadership and hard work of Congressmen Ed Whitfield... Continue Reading

May Is National Skin Cancer Detection and Prevention Month (May 1, 2014)

Sun Valley, ID & Fort Worth, TX—OMNI Health Media (OMNI) announces the launch of skin cancer programs for national skin cancer detection and prevention month. As the month of May brings skin cancer into focus, it’s time to increase public understanding... Continue Reading

Viagra Associated with Increased Risk of Melanoma (April 18, 2014)

Men who take by Viagra (sildenafil) are 84 percent more likely to develop melanoma than men who do not, according to the results of a study published in JAMA Internal Medicine. Melanoma is a potentially fatal type of skin cancer that begins in the melanocytes,... Continue Reading

More Screening and Prevention

Stages I-II

Melanoma Research News: Year in Review (January 7, 2015)

After several years of exciting developments in melanoma therapy, progress continued throughout 2014. Doctors specializing in the treatment of melanoma reported continued progress about optimizing the use of BRAF inhibitors and the long awaited PD-1 immunotherapy... Continue Reading

Yervoy® May be Beneficial in Uveal Melanoma (December 8, 2014)

CancerConnect News:The first trial of the immunomodulator Yervoy® (ipilimumab) conducted in patients with uveal melanoma appears promising in according to the results of a small clinical trial presented at the recent Society of Melanoma Research (SMR)... Continue Reading

PV-10 Injection Promising Treatment of Melanoma Lesions (November 25, 2014)

The results of an international clinical trial evaluating the use of intralesional rose bengal (PV-10), injected in 80 patients with refractory cutaneous or subcutaneous metastatic melanoma were recently reported. PV-10 is a 10% solution of Rose Bengal,... Continue Reading

Thin Melanomas Responsible for Many Melanoma Related Deaths (November 19, 2014)

According to a new study published in The Journal of Investigative Dermatology, more people are dying from melanomas thinner than a dime than from thicker skin lesions, which have long been thought to be more dangerous. Researchers in Australia wanted... Continue Reading

Melanoma More Deadly in Young White Men than Women (August 12, 2013)

Adolescent and young white men with melanoma are more than 50 percent more likely than their female counterparts to die from the disease, according to the results of a study published in JAMA Dermatology.[1] Melanoma is a deadly type of skin cancer that... Continue Reading

More Stages I-II

Stage III

Melanoma Research News: Year in Review (January 7, 2015)

After several years of exciting developments in melanoma therapy, progress continued throughout 2014. Doctors specializing in the treatment of melanoma reported continued progress about optimizing the use of BRAF inhibitors and the long awaited PD-1 immunotherapy... Continue Reading

Yervoy® May be Beneficial in Uveal Melanoma (December 8, 2014)

CancerConnect News:The first trial of the immunomodulator Yervoy® (ipilimumab) conducted in patients with uveal melanoma appears promising in according to the results of a small clinical trial presented at the recent Society of Melanoma Research (SMR)... Continue Reading

PV-10 Injection Promising Treatment of Melanoma Lesions (November 25, 2014)

The results of an international clinical trial evaluating the use of intralesional rose bengal (PV-10), injected in 80 patients with refractory cutaneous or subcutaneous metastatic melanoma were recently reported. PV-10 is a 10% solution of Rose Bengal,... Continue Reading

Progress in the Treatment of Advanced Melanoma and Other Skin Cancers (November 14, 2014)

Online Melanoma Support Group By one estimate, over the past three decades more people in the United States have had skin cancer than all other cancers combined.1 According to the American Cancer Society, 3.5 million cases of basal and squamous cell skin... Continue Reading

COMBI-v BRAF/MEK Inhibitor Combination Trial Impressive in Melanoma (October 8, 2014)

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology Meeting this week. Of the more than one million new diagnoses of skin cancer... Continue Reading

More Stage III

Stage IV

Moffitt Researchers Discover Mechanism Leading to Drug Resistance, Metastasis in Melanoma Patients (January 9, 2015)

TAMPA, Fla. – Moffitt Cancer Center researchers have discovered a mechanism that leads to resistance to targeted therapy in melanoma patients and are investigating strategies to counteract it. Targeted biological therapy can reduce toxicity and improve... Continue Reading

Melanoma Research News: Year in Review (January 7, 2015)

After several years of exciting developments in melanoma therapy, progress continued throughout 2014. Doctors specializing in the treatment of melanoma reported continued progress about optimizing the use of BRAF inhibitors and the long awaited PD-1 immunotherapy... Continue Reading

FDA Approves Nivolumab for Advanced Melanoma (December 23, 2014)

CancerConnect News: The FDA granted accelerated approval to nivolumab (Opdivo) for patients with unresectable or metastatic melanoma who no longer respond to other drugs. Nivolumab, a PD-1 inhibitor, is intended for patients who have been previously treated... Continue Reading

Final Budget Bill Doubles DoD Funding Available for Melanoma Research (December 11, 2014)

The Melanoma Research Alliance (MRA) hailed the inclusion in the omnibus appropriations bill providing government funding for Fiscal Year 2015 of $50 million in funding for the Department of Defense’s (DoD) Peer Reviewed Cancer Research Program (PRCRP),... Continue Reading

Yervoy® May be Beneficial in Uveal Melanoma (December 8, 2014)

CancerConnect News:The first trial of the immunomodulator Yervoy® (ipilimumab) conducted in patients with uveal melanoma appears promising in according to the results of a small clinical trial presented at the recent Society of Melanoma Research (SMR)... Continue Reading

More Stage IV

Recurrent

Moffitt Researchers Discover Mechanism Leading to Drug Resistance, Metastasis in Melanoma Patients (January 9, 2015)

TAMPA, Fla. – Moffitt Cancer Center researchers have discovered a mechanism that leads to resistance to targeted therapy in melanoma patients and are investigating strategies to counteract it. Targeted biological therapy can reduce toxicity and improve... Continue Reading

Melanoma Research News: Year in Review (January 7, 2015)

After several years of exciting developments in melanoma therapy, progress continued throughout 2014. Doctors specializing in the treatment of melanoma reported continued progress about optimizing the use of BRAF inhibitors and the long awaited PD-1 immunotherapy... Continue Reading

FDA Approves Nivolumab for Advanced Melanoma (December 23, 2014)

CancerConnect News: The FDA granted accelerated approval to nivolumab (Opdivo) for patients with unresectable or metastatic melanoma who no longer respond to other drugs. Nivolumab, a PD-1 inhibitor, is intended for patients who have been previously treated... Continue Reading

Yervoy® May be Beneficial in Uveal Melanoma (December 8, 2014)

CancerConnect News:The first trial of the immunomodulator Yervoy® (ipilimumab) conducted in patients with uveal melanoma appears promising in according to the results of a small clinical trial presented at the recent Society of Melanoma Research (SMR)... Continue Reading

PV-10 Injection Promising Treatment of Melanoma Lesions (November 25, 2014)

The results of an international clinical trial evaluating the use of intralesional rose bengal (PV-10), injected in 80 patients with refractory cutaneous or subcutaneous metastatic melanoma were recently reported. PV-10 is a 10% solution of Rose Bengal,... Continue Reading

More Recurrent

CancerConnect Cancer Commuity & Discussions


Cancer Types

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS